Glaxosmithkline plc

Glaxosmithkline plc GSK

Dividend Summary

The next Glaxosmithkline plc dividend went ex 1 month ago for 19p and will be paid in 13 days.
The previous Glaxosmithkline plc dividend was 19p and it went ex 4 months ago and it was paid 3 months ago.
There are typically 4 dividends per year (excluding specials), and the dividend cover is approximately 1.4.

Latest Dividends
Summary Previous dividend Next dividend
Status Paid Declared
Type Quarterly Quarterly
Per share 19p 19p
Declaration date 27 Nov 2020 (Fri) 27 Nov 2020 (Fri)
Ex-div date 20 May 2021 (Thu) 19 Aug 2021 (Thu)
Pay date 08 Jul 2021 (Thu) 07 Oct 2021 (Thu)

Enter the number of Glaxosmithkline plc shares you hold and we'll calculate your dividend payments:

Previous Payment
Next Payment
Forecast Accuracy
100%
Our premium tools have predicted Glaxosmithkline plc with 100% accuracy.
Dividend Yield Today
5.7%
The dividend yield is calculated by dividing the annual dividend payment by the prevailing share price
The table below shows the full dividend history for Glaxosmithkline plc
Status Type Decl. date Ex-div date Pay date Decl. Currency Forecast amount Decl. amount Accuracy
Forecast Quarterly 28 Jan 2026 19 Feb 2026 09 Apr 2026 GBP Sign up
Forecast Quarterly 22 Oct 2025 13 Nov 2025 08 Jan 2026 GBP Sign up
Forecast Quarterly 22 Nov 2024 14 Aug 2025 09 Oct 2025 GBP Sign up
Forecast Quarterly 22 Nov 2024 15 May 2025 10 Jul 2025 GBP Sign up
Forecast Quarterly 29 Jan 2025 20 Feb 2025 10 Apr 2025 GBP Sign up
Forecast Quarterly 23 Oct 2024 14 Nov 2024 09 Jan 2025 GBP Sign up
Forecast Quarterly 24 Nov 2023 15 Aug 2024 10 Oct 2024 GBP Sign up
Forecast Quarterly 24 Nov 2023 16 May 2024 11 Jul 2024 GBP Sign up
Forecast Quarterly 31 Jan 2024 22 Feb 2024 11 Apr 2024 GBP Sign up
Forecast Quarterly 25 Oct 2023 09 Nov 2023 11 Jan 2024 GBP Sign up
Forecast Quarterly 25 Nov 2022 17 Aug 2023 12 Oct 2023 GBP Sign up
Forecast Quarterly 25 Nov 2022 18 May 2023 13 Jul 2023 GBP Sign up
Forecast Quarterly 01 Feb 2023 23 Feb 2023 13 Apr 2023 GBP Sign up
Forecast Quarterly 26 Oct 2022 10 Nov 2022 12 Jan 2023 GBP Sign up
Forecast Quarterly 26 Nov 2021 18 Aug 2022 13 Oct 2022 GBP Sign up
Forecast Quarterly 26 Nov 2021 19 May 2022 14 Jul 2022 GBP Sign up
Forecast Quarterly 02 Feb 2022 24 Feb 2022 07 Apr 2022 GBP Sign up
Forecast Quarterly 27 Oct 2021 18 Nov 2021 13 Jan 2022 GBP Sign up
Declared Quarterly 27 Nov 2020 19 Aug 2021 07 Oct 2021 GBP 19p 19p 😄
Paid Quarterly 27 Nov 2020 20 May 2021 08 Jul 2021 GBP 19p 19p 😄
Paid Quarterly 08 Jan 2020 18 Feb 2021 08 Apr 2021 GBP 23p 23p 😄
Paid Quarterly 08 Jan 2020 12 Nov 2020 14 Jan 2021 GBP 19p 19p 😄
Paid Quarterly 08 Jan 2020 13 Aug 2020 08 Oct 2020 GBP 19p 19p 😄
Paid Quarterly 08 Jan 2020 14 May 2020 09 Jul 2020 GBP 19p 19p 😄
Paid Quarterly 22 Nov 2018 20 Feb 2020 09 Apr 2020 GBP 23p 23p 😄
Paid Quarterly 22 Nov 2018 14 Nov 2019 09 Jan 2020 GBP 19p 19p 😄
Paid Quarterly 22 Nov 2018 08 Aug 2019 10 Oct 2019 GBP 19p 19p 😄
Paid Quarterly 22 Nov 2018 16 May 2019 11 Jul 2019 GBP 19p 19p 😄
Paid Quarterly 30 Aug 2018 21 Feb 2019 11 Apr 2019 GBP 23p 23p 😄
Paid Quarterly 21 Nov 2017 15 Nov 2018 10 Jan 2019 GBP 19p 19p 😄
Paid Quarterly 21 Nov 2017 09 Aug 2018 11 Oct 2018 GBP 19p 19p 😄
Paid Quarterly 21 Nov 2017 10 May 2018 12 Jul 2018 GBP 19p 19p 😄
Paid Quarterly 21 Nov 2017 22 Feb 2018 12 Apr 2018 GBP 23p 23p 😄
Paid Quarterly 26 Jul 2017 09 Nov 2017 11 Jan 2018 GBP 19p 19p 😄
Paid Quarterly 26 Jul 2017 10 Aug 2017 12 Oct 2017 GBP 19p 19p 😄
Paid Quarterly 26 Apr 2017 11 May 2017 13 Jul 2017 GBP 19p
Paid Quarterly 26 Oct 2016 23 Feb 2017 13 Apr 2017 GBP 23p 23p 😄
Paid Quarterly 17 Mar 2016 03 Nov 2016 12 Jan 2017 GBP 19p 19p 😄
Paid Quarterly 17 Mar 2016 11 Aug 2016 13 Oct 2016 GBP 19p 19p 😄
Paid Quarterly 17 Mar 2016 12 May 2016 14 Jul 2016 GBP 19p 19p 😄
Paid Special 06 May 2015 18 Feb 2016 14 Apr 2016 GBP 20p
Paid Quarterly 28 Oct 2015 18 Feb 2016 14 Apr 2016 GBP 23p
Paid Quarterly 27 Feb 2015 12 Nov 2015 14 Jan 2016 GBP 19p
Paid Quarterly 26 Feb 2015 13 Aug 2015 01 Oct 2015 GBP 19p
Paid Quarterly 26 Feb 2015 14 May 2015 09 Jul 2015 GBP 19p
Paid Quarterly 04 Feb 2015 19 Feb 2015 09 Apr 2015 GBP 23p
Paid Quarterly 27 Feb 2014 06 Nov 2014 08 Jan 2015 GBP 19p
Paid Quarterly 27 Feb 2014 06 Aug 2014 02 Oct 2014 GBP 19p
Paid Quarterly 27 Feb 2014 14 May 2014 10 Jul 2014 GBP 19p
Paid Quarterly 05 Feb 2014 19 Feb 2014 10 Apr 2014 GBP 23p
Paid Quarterly 23 Oct 2013 13 Nov 2013 09 Jan 2014 GBP 19p
Paid Quarterly 07 Aug 2013 03 Oct 2013 GBP 18p
Paid Quarterly 08 May 2013 11 Jul 2013 GBP 18p
Paid Quarterly 20 Feb 2013 11 Apr 2013 GBP 22p
Paid Quarterly 14 Nov 2012 03 Jan 2013 GBP 18p
Paid Quarterly 08 Aug 2012 04 Oct 2012 GBP 17p
Paid Quarterly 09 May 2012 05 Jul 2012 GBP 17p
Paid Quarterly 02 Nov 2011 05 Jan 2012 GBP 17p
Paid Quarterly 03 Aug 2011 06 Oct 2011 GBP 16p
Paid Quarterly 04 May 2011 07 Jul 2011 GBP 16p
Paid Quarterly 09 Feb 2011 07 Apr 2011 GBP 19p
Paid Quarterly 27 Oct 2010 06 Jan 2011 GBP 16p
Paid Quarterly 28 Jul 2010 07 Oct 2010 GBP 15p
Paid Quarterly 05 May 2010 08 Jul 2010 GBP 15p
Paid Final 31 Dec 2009 31 Dec 2009 GBP 61p
Paid Final 31 Dec 2008 31 Dec 2008 GBP 57p
Paid Final 31 Dec 2007 31 Dec 2007 GBP 53p
Paid Final 31 Dec 2006 31 Dec 2006 GBP 48p
Year Amount Change
2006 48.0p
2007 53.0p
10.4%
2008 57.0p
7.5%
2009 61.0p
7.0%
2010 65.0p
6.6%
2011 49.0p
-24.6%
2012 74.0p
51.0%
2013 78.0p
5.4%
2014 80.0p
2.6%
2015 80.0p
0%
2016 80.0p
0%
2017 80.0p
0%
2018 80.0p
0%
2019 80.0p
0%
2020 80.0p
0%
2021 Sign Up Required
2022 Sign Up Required
2023 Sign Up Required
2024 Sign Up Required
2025 Sign Up Required

Glaxosmithkline plc Optimized Dividend Chart

The chart below shows the optimized dividends for this security over a rolling 12-month period.
Dividend Yield Today
5.7%
Optimized Yield
Sign Up Required
52 Week High
9.5% on 17 February 2021
52 Week Low
5.5% on 19 August 2021
Next Ex-Div-Date Countdown
Sign Up Required

About Glaxosmithkline plc

GlaxoSmithKline is a very large UK based pharmaceutical company with an excellent track record of delivering increased dividends to shareholders. In recent years it has been changing its strategy and reducing it's dependence on the pure pharmaceuticals business.

Sector
Pharmaceuticals & Biotechnology
Country
United Kingdom
Share Price
£14.14 (yesterday's closing price)
Shares in Issue
4,850 million
Market Cap
£68.6bn
Dividend Cover
How many times is the dividend covered by company income. A cover of 1 means all income is paid out in dividends
1.4
CADI
The Consecutive Annual Dividend Increases - the number of years this company has been increasing its dividends
0
Market Indices
S&P Global 100, FTSE Eurotop 100, STOXX600, FTSE 350, FTSE 100, CBOE 350, CBOE 100
Home Page URL
https://www.gsk.com/
Investor Relations URL
Sign Up Required
Dividend History URL
Sign Up Required
Financial Calendar URL
Sign Up Required
DividendMax Limited
Summary · Group sales +6% CER on a reported basis and +1% CER pro-forma - Pharmaceuticals £14.2 billion, -7% (-1% pro-forma); Vaccines £3.7 billion, +19% (+3% pro-forma); Consumer Healthcare £6 billion, +44% (+6% pro-forma) · £2 billion of new product sales driven by HIV (Tivicay, Triumeq), Respiratory (Relvar/Breo, Anoro,Incruse) and Meningitis vaccines (Menveo, Bexsero) - Growing sales contribution: Q4 sales £682 million, (Q3: £591 million) - Nucala, a new biologic treatment for severe asthma, launched at the end of 2015 - New product sales now expected to reach £6 billion target up to two years earlier (2018 vs 2020) · Integration and restructuring programme on schedule - £1 billion incremental annual cost savings delivered in 2015 for costs of £1.9 billion - On track to deliver £3 billion of annual cost savings by end 2017 · 2015 core EPS 75.7p, -15% CER, ahead of financial guidance - Reflects short-term dilution from transaction partly offset by integration and restructuring benefits · 2015 total EPS 174.3p, +>100% CER - Reflects impact of transaction gains, partly offset by restructuring charges and revaluation of the contingent consideration relating to improved outlook for HIV business · 2016 core EPS percentage growth expected to reach double digits CER - If FX rates held at January average levels estimated impact of +5% on 2016 Sterling core EPS growth · 2015 ordinary dividend of 80p and special dividend of 20p confirmed - Special dividend to be paid alongside Q4 ordinary dividend in April 2016 - Continue to expect 80p full year dividend for 2016 and 2017 · New R&D portfolio of ~40 assets to drive long-term performance; multiple development milestones expected in 2016/2017 - Up to 10 regulatory filings include Shingrix (shingles vaccine), sirukumab (RA), Benlysta SC (lupus) and ICS/LABA/LAMA (COPD) - Up to 10 Phase lll starts include cabotegravir (HIV), daprodustat (anaemia) and Men ABCWY vaccine - Up to 20 Phase ll starts in Immuno-inflammation, Oncology, Respiratory and Infectious diseases - Estimated R&D rate of return maintained at 13%
DividendMax Limited
Summary · Group sales +7% CER on a reported basis and +2% CER pro-forma - Pharmaceuticals £3.5 billion, -6% (+2% pro-forma); Vaccines £0.8 billion, +11% (-5% pro-forma); Consumer Healthcare £1.5 billion, +51% (+6% pro-forma) - New Pharmaceutical and Vaccine sales of £446 million in Q2 · Q2 core EPS of 17.3p, flat in CER terms - EPS reflects dilution of Novartis transaction, ongoing pricing pressure partly offset by cost reductions - Integration of new Consumer and Vaccine businesses on track - On track to deliver targeted annual cost savings of £3 billion from all restructuring programmes · Total Q2 EPS of 3.1p and H1 EPS of 170.7p - Reflects phasing of pre-tax transaction gains and accelerated restructuring charges · 2015 earnings guidance and 2016 outlook reiterated - Expect 2015 core EPS to decline at a high teen percentage rate (CER) - 2016 core EPS percentage growth expected to reach double digits (CER) · Q2 dividend of 19p declared - Continued expectation for full year dividend of 80p · R&D innovation with significant potential to drive long-term Group performance - Progress of new respiratory portfolio continues with positive FDA AdCom recommendation for Nucala and regulatory filing for approval in Japan - Positive CHMP decision received for Mosquirix - Group has ~40 NMEs (drugs and vaccines) in Phase II/III clinical development, primarily focused on HIV, Oncology, Vaccines, Cardiovascular, Immuno-inflammation and Respiratory diseases - New data and prospects for advanced/early-stage pipeline to be reviewed at R&D event in November
DividendMax Limited
DividendMax Limited
DividendMax Limited
Summary ■ Broadly-based sales growth with Group turnover +1% CER:   - Pharmaceuticals and Vaccines sales flat: US +2%, Europe +5%, Japan +2% offset by EMAP -9%, impacted by decline in China sales and Vaccines phasing   - Consumer Healthcare +4%   - Total Group turnover ex-divestments +1%     ■ Further significant pipeline approvals and filings:   - 4 approvals; US: Tivicay for HIV and FluLaval Q-IV vaccine for flu; Europe: Tafinlar for metastatic melanoma; Japan: Relvar Ellipta for asthma   - Positive FDA Adcom recommendation for Anoro Ellipta in COPD and positive CHMP opinion for Relvar Ellipta in asthma & COPD   - 3 FDA filings: Arzerra for first-line CLL; dolutegravir-Trii for HIV; fluticasone furoate monotherapy for asthma     ■ Continued delivery of operating and financial efficiencies, strong cash generation and returns to shareholders:   - Net cash inflow from operating activities of £2.1 billion; core tax rate 23.5%   - Core EPS 28.9p (+16%) benefiting from operating, financial and long-term cost efficiencies   - Q3 dividend: 19p (+6%)   - £1 billion of shares repurchased by the end of Q3; continue to target £1-2 billion for the year       ■ Successful implementation of measures to drive strategic focus and improve growth outlook:   - Agreement to divest Lucozade and Ribena to Suntory for £1.35 billion and Arixtra/Fraxiparine and related manufacturing site to Aspen for £700 million     ■ Full year 2013 guidance reaffirmed:   - Core EPS growth of 3-4% on sales growth of around 1% (both CER)
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited